China SXT Pharmaceuticals, Inc. revenue

China SXT Pharmaceuticals, Inc.'s revenue was $1.1m in fiscal 2026, down 34.6% on the year before. Since fiscal 2017 ($4.9m) it has grown at a compound -14.9% a year.

Revenue history

US$ thousands unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

China SXT Pharmaceuticals, Inc.: revenue history, annual
Fiscal year	2017Mar 2017	2018Mar 2018	2019Mar 2019	2020Mar 2020	2021Mar 2021	2022Mar 2022	2023Mar 2023	2024Mar 2024	2025Mar 2025	2026Mar 2026
Revenue	4,882	7,019	7,012	5,162	4,778	2,602	1,972	1,928	1,741	1,138
Growth on the year before	—	+43.8%	−0.1%	−26.4%	−7.5%	−45.5%	−24.2%	−2.2%	−9.7%	−34.6%
Gross profit	2,312	3,401	4,612	2,704	2,840	1,252	426	554	367	249
Gross margin	47.4%	48.5%	65.8%	52.4%	59.4%	48.1%	21.6%	28.7%	21.1%	21.9%

Revenue as reported in the company's 10-K and 10-Q filings (for banks, net interest income plus non-interest income). Growth is left blank when the earlier figure was zero or negative.

Revenue against peers

Pharmaceuticals: the closest covered companies by revenue. Last twelve months.

Company	Revenue	Growth	3-year growth a year
China SXT Pharmaceuticals, Inc.	$1.1m	-34.6%	—
60 Degrees Pharmaceuticals, Inc.	$1.1m	73.2%	74.9%
Lipocine Inc.	$1.6m	-62.7%	205.6%
Scienture Holdings, Inc.	$821,315	540.6%	-58.5%
Nutriband Inc.	$1.6m	-37.3%	-10.8%
Eyepoint, Inc.	$2.8m	-94.6%	-57.9%

Compare with peers

Head to head: SXTC vs SXTP LPCN vs SXTC SCNX vs SXTC NTRB vs SXTC

More: Pharmaceuticals stocks compared, Health Care sector, rankings of US companies

Figures from China SXT Pharmaceuticals, Inc.'s SEC filings (10-K and 10-Q). How we read and check them: methodology and data sources. Not investment advice. Back to China SXT Pharmaceuticals, Inc.